The ShortCut™ Study Protocol

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

December 31, 2023

Conditions
Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure
Interventions
DEVICE

ShortCut™

Splitting bioprosthetic aortic valve leaflets

Trial Locations (23)

10032

Columbia University Medical Center, New York

17043

UPMC Pinnacle, Wormleysburg

20010

Medstar Washington Hospital Center, Washington D.C.

28204

Carolinas Medical Center / Atrium Health, Charlotte

48109

University of Michigan, Ann Arbor

60453

Advocate Christ Medical Center, Oak Lawn

75093

Baylor Scott & White, The Heart Hospital Plano, Plano

84107

Intermountain Medical Center, Murray

85712

Tucson Medical Center, Tucson

90048

Smidt Heart Institute Cedars-Sinai Medical, Los Angeles

91360

Los Robles Regional Medical Center, Thousand Oaks

94115

Kaiser Permanente - San Francisco Medical Center, San Francisco

07960

Morristown Medical Center, Morristown

Unknown

CHU de Bordeaux (Bordeaux University Hospital), Bordeaux

Institute Mutualiste Montsouris, Paris

Clinique Pasteur, Toulouse

German Heart Institute Berlin, Berlin

University Hospital Hamburg, Hamburg

Leipzig Heart Institute, Leipzig

Sha'are Tzedek Medical Center, Jerusalem

Rabin Medical Center, Petah Tikva

Royal Sussex County Hospital, Brighton

Leeds General Infirmary, Leeds

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pi-cardia

INDUSTRY

NCT04952909 - The ShortCut™ Study Protocol | Biotech Hunter | Biotech Hunter